SANT'ANTONIO, EMANUELA
 Distribuzione geografica
Continente #
NA - Nord America 472
EU - Europa 246
AS - Asia 72
OC - Oceania 2
Totale 792
Nazione #
US - Stati Uniti d'America 471
RU - Federazione Russa 116
IT - Italia 46
SG - Singapore 25
CN - Cina 24
IE - Irlanda 22
CH - Svizzera 17
HK - Hong Kong 17
DE - Germania 13
SE - Svezia 9
FI - Finlandia 8
ES - Italia 7
FR - Francia 4
JO - Giordania 3
AU - Australia 2
GB - Regno Unito 2
NL - Olanda 2
CA - Canada 1
ID - Indonesia 1
IN - India 1
SA - Arabia Saudita 1
Totale 792
Città #
Santa Clara 167
Fairfield 43
Chandler 34
Ashburn 33
Seattle 26
Dublin 22
Woodbridge 18
Bern 17
Wilmington 17
Singapore 15
Houston 13
Cambridge 12
Hong Kong 12
Altamura 10
Moscow 10
Beijing 9
Lawrence 9
Princeton 7
Helsinki 6
Kent 6
Ann Arbor 5
Barcelona 5
Boston 4
Buffalo 4
Florence 4
Shanghai 4
Yubileyny 4
New York 3
Norwalk 3
San Jose 3
Bremen 2
Costa Mesa 2
Fiesole 2
Los Angeles 2
Medford 2
Melbourne 2
Nürnberg 2
Recanati 2
Redwood City 2
Reston 2
Seville 2
Azzano San Paolo 1
Brugherio 1
Catania 1
Dearborn 1
Falkenstein 1
Fiumicino 1
Fremont 1
Fuyang 1
Fuzhou 1
Hounslow 1
Jakarta 1
Leawood 1
Livorno 1
Montreal 1
Mumbai 1
Munich 1
Pesaro 1
Riyadh 1
Rome 1
Sarcedo 1
Scarperia e San Piero 1
Washington 1
Totale 569
Nome #
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 182
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 167
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 109
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice 101
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 95
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 81
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 74
Totale 809
Categoria #
all - tutte 2.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.727


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202059 0 0 0 0 0 0 14 14 13 9 8 1
2020/202161 4 2 0 15 1 1 11 12 5 4 6 0
2021/202232 2 0 1 2 0 1 0 6 4 0 5 11
2022/2023142 10 27 10 7 10 19 15 9 11 2 2 20
2023/202492 2 5 11 6 13 11 0 19 1 9 12 3
2024/2025352 12 30 29 71 136 68 6 0 0 0 0 0
Totale 809